Introduction {#S1}
============

Aortic valve calcification (AVC) is a major determinant in leaflet stiffening and progression of aortic valve disease. AVC, also known as calcific aortic valve disease (CAVD), calcific aortic valve stenosis (CAVS), or aortic valve stenosis (AS), is a spectrum of disease, ranging from aortic valve sclerosis to severe AS. Aortic valve sclerosis is defined as diffuse thickening of the aortic valve without significant blood flow obstruction. The occurrence of aortic valve sclerosis is common, even in relatively young populations: its incidence increases from 1.9 to 8.8% with increasing age and its prevalence is ∼40% in patients \>75 years. Moreover, it is associated with increased cardiovascular risk ([@B14], [@B13]). Over time, aortic valve disease progresses slowly, and ∼2% of patients develop hemodynamically significant AS per year ([@B25]; [@B26]). Aortic valve stenosis is defined as narrowing of the valve causing blood flow obstruction.

With an increasingly elderly population, disease burden of aortic valve stenosis will increase in the coming years. Due to the complexity, challenges, and cost of management, the number of patients with an indication for treatment is expected to double by 2050 in Europe and the United States ([@B27]). Whereas aortic valve stenosis was considered a passive disease whereby by "wear and tear" resulted in calcification of the valve, emerging evidence showed that it is an active disease, involving highly complex and tightly regulated pathways ([@B31]; [@B29]). However, we still lack precise molecular insight in pathophysiological processes and their exact contribution to aortic valve stenosis and its progression.

Pathophysiological mechanisms involved in the initiation and progression of aortic valve disease are being rapidly elucidated, but their exact contribution and extent of their involvement remain to be investigated ([@B16]). Whereas aortic valve disease used to be considered a passive and degenerative process, it is now appreciated to be an active process with involvement of multiple cellular and molecular pathways in inflammation, fibrosis and calcification. Calcification is one of the critical processes in AS progression ([@B28]; [@B6]; [@B29]; [@B30]). Sex specificity of processes involved are suggested to be present in aortic valve disease, yet are largely unresolved ([@B37]). The extent of contribution of calcification as well as fibrosis to the progression of AS is a matter of debate and seems related to sex differences ([@B20]). Aortic valves of women with severe AS show less AVC on CT when compared to men with similar hemodynamic severity of AS, but similar progression rates were found in males and females ([@B1]; [@B11], [@B12]; [@B38]). Recently, it was hypothesized that more valvular fibrosis might explain the basis of this sex-related discrepancy between the AVC load and hemodynamic severity in females ([@B36]). Insight into molecular calcification processes may help to define appropriate interventions to halt or reduce progression.

Once present, AVC progresses and development of hemodynamically evident aortic valve disease is a common feature, requiring regular monitoring using echocardiography (and computed tomography). Addition of biomarkers to optimize risk assessment of progressive diseases would be useful from the initial phase onward. The ESC guidelines only integrate a possible role for NTproBNP in timing of aortic valve replacement though ([@B5]). This might be due to the fact that most studies focus on the identification of biomarkers in patients with advanced aortic valve disease.

Therefore, we aimed to explore the differences in circulating biomarkers holding potential for further investigation in the early phase of AVC in a low risk population.

Materials and Methods {#S2}
=====================

Study Population {#S2.SS1}
----------------

In this cross-sectional observational study, patients without clinically overt vascular disease (other than lone atrial fibrillation) who underwent cardiac Computed Tomography (CT) (January 2008--March 2011) in the work-up for pulmonary vein isolation or general screening were screened. EDTA-plasma was available from 180 patients and these were selected for this study. Ten patients were excluded, as biomarker analysis in those patients returned a value within the limits of detection for less than 15% of the proteins, due to a technical error in the measurement. Thus, 170 patients (*n* = 48 atrial fibrillation, *n* = 122 sinus rhythm) constituted the final population for the current study. This study was approved by the Institutional Review Board.

Computed Tomography {#S2.SS2}
-------------------

All patients underwent a non-contrast enhanced coronary calcium scan as described previously, performed on a Philips Brilliance 64-slice MSCT scanner (Brilliance 64; Philips Healthcare, Best, Netherlands) or a 2nd generation Dual source CT scanner (Siemens Somatom Definition Flash 2^∗^128-slice, Siemens Healthineers, Forchheim, Germany) ([@B40]). Quantitative assessment (expressed as Agatston scores) of AVC was performed by two independent observers. Presence of AVC was defined as Agatston score \>0.

Biomarkers {#S2.SS3}
----------

Proteins were quantified by real-time PCR in all EDTA-plasma samples using the Olink Proseek Multiplex Cardiovascular I kit (Olink Proteomics, Uppsala, Sweden), as described previously ([@B4]). Interleukin 4 (IL4), Natriuretic Peptides B (BNP), and Melusin (ITGB1BP2) were excluded from further analyses due to low call rates (valid measurement in \<85% of samples). Values below the Limit of Detection (LOD) were replaced by the LOD value^[1](#footnote1){ref-type="fn"}^. Data from the panels were normalized to the median of 0 for each protein, enabling comparisons between measurements from different panels. The panel provides NPX-values which allow for relative quantification comparisons for the same protein across samples.

Statistical Analyses {#S2.SS4}
--------------------

Statistical analyses were performed using SPSS version 22 (IBM Corp., Armonk, NY, United States). Normally distributed continuous variables are expressed as mean ± standard deviation (SD) and compared using the independent samples *t*-test, non-normally distributed continuous variables as median (interquartile range; IQR) and compared using the Mann-Whitney *U* test. Categorical variables are expressed as absolute numbers and percentages and tested using the Fishers exact test.

Logistic regression adjusted for age, presence of AF (and sex when appropriate) was used to determine the association between biomarkers and calcification with AVC or no AVC as the outcome. Odds ratios and 95% confidence intervals (CI) were calculated and *p* \<0.05 was considered significant.

Results {#S3}
=======

Aortic Valve Calcification on CT {#S3.SS1}
--------------------------------

AVC was present in 34 patients: 11 females, 23 males (median \[IQR\] Agatston scores of the total, female and male populations were 11.3 \[47.6\], 15.8 \[69.2\], and 11.2 \[40.8\] respectively). In general, patients with AVC were older than patients without AVC (mean age 59 ± 6 vs. 53 ± 10 years in patients with vs. without AVC, *p* \< 0.001). Other baseline characteristics were not significantly different ([Supplementary Table 1](#TS1){ref-type="supplementary-material"}). A detailed description of the study population was published previously ([@B40]).

Biomarkers and Valvular Calcification {#S3.SS2}
-------------------------------------

[Table 1](#T1){ref-type="table"} shows the age, sex and AF adjusted OR (and 95% CI) of all biomarkers. In the total population, Interleukin 1 receptor antagonist protein (IL1RA) was associated with increased odds of having AVC \[OR 2.29 (1.13--4.65), *p* = 0.022\]. Furthermore, pappalysin-1 (PAPPA) was associated with decreased odds of having AVC \[OR 0.37 (0.16--0.87), *p* = 0.023\] ([Figure 1A](#F1){ref-type="fig"}).

###### 

Odds ratios for 89 biomarkers (corrected for age, sex, and atrial fibrillation) in the total population with and without aortic valve calcification and subdivided in female and male populations.

                                                                 Total population        Female      Male                                                            
  -------------------------------------------------------------- ----------------------- ----------- --------------------------- ----------- ----------------------- -----------
  Adrenomedullin (AM)                                            0.828 (0.276--2.479)    0.894       1.891 (0.204--17.499)       0.575       0.571 (0.145--2.240)    0.422
  Agouti−related protein (AGRP)                                  0.878 (0.397--1.945)    0.749       2.179 (0.298--15.954)       0.443       0.646 (0.259--1.615)    0.350
  Angiopoietin-1 receptor (TIE2)                                 0.906 (0.239--3.437)    0.884       29.457 (0.461--1881.605)    0.111       0.412 (0.088--1.925)    0.259
  Beta-nerve growth factor (Beta-NGF)                            0.775 (0.241--2.490)    0.668       1.804 (0.081--40.356)       0.710       0.642 (0.170--2.425)    0.513
  Cancer antigen 125 (CA125)                                     0.982 (0.497--1.941)    0.959       1.097 (0.251--4.796)        0.902       1.007 (0.459--2.212)    0.986
  Caspase 8 (CASP8)                                              0.989 (0.532--1.840)    0.973       0.836 (0.265--2.633)        0.759       1.089 (0.531--2.232)    0.816
  Cathepsin D (CTSD)                                             1.313 (0.560--3.079)    0.532       4.289 (0.553--33.247)       0.163       1.119 (0.415--3.015)    0.824
  Cathepsin L1 (CTSL1)                                           1.654 (0.474--5.771)    0.430       5.412 (0.142--206.068)      0.363       1.322 (0.340--5.147)    0.687
  C-C motif chemokine 3 (CCL3)                                   1.528 (0.501--4.660)    0.456       0.786 (0.090--6.881)        0.827       1.651 (0.430--6.340)    0.466
  C-C motif chemokine 4 (CCL4)                                   1.539 (0.850--2.786)    0.154       1.033 (0.392--2.725)        0.948       1.655 (0.781--3.510)    0.189
  C-C motif chemokine 20 (CCL20)                                 1.225 (0.846--1.774)    0.283       1.472 (0.546--3.965)        0.444       1.256 (0.839--1.880)    0.268
  CD40 ligand (CD40L)                                            0.705 (0.422--1.180)    0.183       0.971 (0.349--2.699)        0.955       0.659 (0.363--1.194)    0.169
  CD40L receptor (CD40)                                          0.599 (0.224--1.603)    0.307       1.849 (0.187--18.290)       0.599       0.400 (0.121--1.330)    0.135
  Chitinase−3−like protein 1 (CHI3L1)                            1.241 (0.751--2.050)    0.399       1.134 (0.411--3.128)        0.808       1.302 (0.719--2.356)    0.383
  C-X−C motif chemokine 1 (CXCL1)                                0.629 (0.374--1.058)    0.080       0.688 (0.233--2.032)        0.499       0.660 (0.369--1.180)    0.161
  C-X−C motif chemokine 6 (CXCL6)                                0.868 (0.503--1.498)    0.610       1.040 (0.494--2.190)        0.917       0.555 (0.227--1.356)    0.196
  C-X−C motif chemokine 16 (CXCL16)                              1.416 (0.401--4.999)    0.589       10.291 (0.424--249.714)     0.152       0.876 (0.204--3.755)    0.859
  Cystatin B (CSTB)                                              1.194 (0.650--2.193)    0.567       1.195 (0.380--3.761)        0.760       1.315 (0.627--2.760)    0.468
  Dickkopf−related protein 1 (DKK1)                              0.642 (0.315--1.311)    0.224       0.773 (0.199--3.010)        0.711       0.663 (0.284--1.547)    0.341
  Endothelial cell−specific molecule 1 (ESM1)                    0.696 (0.280--1.733)    0.436       1.203 (0.232--6.235)        0.826       0.508 (0.154--1.673)    0.266
  Eosinophil cationic protein (ECP)                              1.060 (0.544--2.066)    0.864       0.280 (0.051--1.524)        0.141       1.615 (0.762--3.425)    0.211
  Epidermal growth factor (EGF)                                  0.662 (0.425--1.032)    0.069       0.696 (0.284--1.705)        0.428       0.669 (0.403--1.111)    0.120
  E-selectin (SELE)                                              0.978 (0.490--1.951)    0.949       1.339 (0.288--6.236)        0.710       1.051 (0.462--2.389)    0.906
  Fatty acid−binding protein 4 (FABP4)                           0.894 (0.373--2.142)    0.801       1.377 (0.142--13.348)       0.783       0.799 (0.291--2.193)    0.663
  Fibroblast growth factor 23 (FGF23)                            0.699 (0.376--1.297)    0.256       1.417 (0.451--4.456)        0.551       0.410 (0.170--0.991)    **0.048**
  Follistatin (FS)                                               0.835 (0.354--1.968)    0.835       0.790 (0.163--3.823)        0.769       0.970 (0.329--2.859)    0.955
  Fractalkine (CX3CL1)                                           1.148 (0.397--3.319)    0.798       2.823 (0.349--22.850)       0.331       0.559 (0.150--2.090)    0.388
  Galanin peptides (GAL)                                         1.437 (0.723--2.853)    0.301       12.381 (1.314--116.694)     **0.028**   0.867 (0.405--1.859)    0.715
  Galectin 3 (GAL3)                                              1.000 (0.443--2.255)    \> 0.999    1.276 (0.321--5.072)        0.729       0.825 (0.304--2.238)    0.705
  Growth/differentiation factor 15 (GDF-15)                      1.218 (0.543--2.729)    0.632       0.968 (0.088--10.710)       0.979       1.222 (0.515--2.900)    0.650
  Growth hormone (GH)                                            0.976 (0.801--1.189)    0.806       1.227 (0.724--2.080)        0.447       0.908 (0.715--1.154)    0.430
  Heat shock 27 kDa protein (HSP27)                              0.839 (0.549--1.284)    0.419       0.940 (0.383--2.306)        0.940       0.803 (0.490--1.316)    0.384
  Heparin-binding EGF−like growth factor (HB-EGF)                0.355 (0.094--1.345)    0.128       0.524 (0.039--7.092)        0.627       0.317 (0.067--1.510)    0.149
  Hepatocyte growth factor (HGF)                                 0.942 (0.419--2.121)    0.886       0.970 (0.245--3.850)        0.966       1.339 (0.389--4.612)    0.644
  Interleukin 1 receptor antagonist protein (IL1RA)              2.289 (1.126--4.651)    **0.022**   2.192 (0.469--10.245)       0.319       2.790 (1.163--6.695     **0.022**
  Interleukin 6 (IL6)                                            1.296 (0.859--1.957)    0.217       1.315 (0.455--3.803)        0.613       1.326 (0.824--2.133)    0.245
  Interleukin-6 receptor subunit alpha (IL6RA)                   0.739 (0.281--1.941)    0.539       0.954 (0.126--7.239)        0.964       0.763 (0.243--2.392)    0.763
  Interleukin 8 (IL8)                                            1.713 (0.829--3.542)    0.146       1.007 (0.321--3.161)        0.991       2.698 (1.001--7.270)    0.050
  Interleukin 16 (IL16)                                          1.033 (0.463--2.306)    0.937       2.637 (0.233--29.828)       0.433       0.871 (0.364--2.084)    0.757
  Interleukin 18 (IL18)                                          0.831 (0.377--1.828)    0.645       1.457 (0.282--7.529)        0.653       0.746 (0.302--1.845)    0.526
  Interleukin-27 subunit alpha (IL27A)                           2.216 (0.645--7.617)    0.206       2.004 (0.204--19.706)       0.551       1.986 (0.449--8.779)    0.366
  Kallikrein 6 (KLK6)                                            1.270 (0.441--2.660)    0.658       17.093 (0.713--409.697)     0.080       0.681 (0.200--2.310)    0.537
  Kallikrein 11 (hK11)                                           0.898 (0.329--2.453)    0.834       3.081 (0.355--26.763)       0.308       0.667 (0.208--2.141)    0.496
  Lectin−like oxidized LDL receptor 1 (LOX1)                     1.012 (0.513--1.995)    0.972       0.965 (0.211--4.417)        0.963       1.150 (0.530--2.499)    0.723
  Leptin (LEP)                                                   1.705 (0.992--2.929)    0.053       3.294 (0.828--13.098)       0.091       1.617 (0.853--3.068)    0.141
  Macrophage colony stimulating factor (CSF1)                    2.330 (0.410--13.245)   0.340       5.189 (0.141--190.728)      0.371       1.709 (0.219--13.309)   0.609
  Matrix metalloproteinase 1 (MMP1)                              0.863 (0.463--1.607)    0.641       0.945 (0.308--2.894)        0.920       1.002 (0.452--2.220)    0.996
  Matrix metalloproteinase 3 (MMP3)                              0.998 (0.500--1.990)    0.995       5.854 (0.932--36.759)       0.059       0.562 (0.218--1.446)    0.232
  Matrix metalloproteinase (MMP7)                                1.517 (0.687--3.349)    0.302       1.731 (0.433--6.918)        0.438       1.518 (0.564--4.089)    0.409
  Matrix metalloproteinase (MMP10)                               1.278 (0.651--2.510)    0.476       1.793 (0.469--6.863)        0.394       1.133 (0.492--2.607)    0.770
  Matrix metalloproteinase 12 (MMP12)                            1.583 (0.888--2.823)    0.119       1.121 (0.293--4.297)        0.867       1.600 (0.836--3.059)    0.156
  Membrane−bound aminopeptidase P (mAmP)                         1.031 (0.711--1.494)    0.874       1.220 (0.536--2.775)        0.636       0.892 (0.573--1.387)    0.612
  Monocyte chemotactic protein 1 (MCP1)                          2.098 (0.922--4.772)    0.077       0.880 (0.128--6.069)        0.897       2.635 (1.021--6.805)    **0.045**
  Myeloperoxidase (MPO)                                          1.011 (0.268--3.821)    0.987       1.535 (0.064--37.027)       0.792       0.784 (0.165--3.723)    0.760
  Myoglobin (MB)                                                 1.387 (0.688--2.793)    0.360       2.616 (0.466--14.682)       0.274       1.009 (0.445--2.288)    0.983
  NF−kappa−B essential modulator (NEMO)                          0.664 (0.365--1.206)    0.179       0.562 (0.146--2.166)        0.403       0.722 (0.377--1.384)    0.327
  N−terminal pro −B−type natriuretic peptide (NT-proBNP)         0.938 (0.617--1.426)    0.766       0.976 (0.356--2.680)        0.963       0.841 (0.521--1.356)    0.477
  Osteoprotegerin (OPG)                                          1.449 (0.500--4.197)    0.495       2.777 (0.384--20.076)       0.311       1.246 (0.320--4.857)    0.751
  Pappalysin−1 (PAPPA)                                           0.367 (0.155--0.870)    **0.023**   0.644 (0.088--4.738)        0.666       0.303 (0.110--0.836)    **0.021**
  Pentraxin-related protein PTX3 (PTX3)                          0.564 (0.234--1.358)    0.201       0.878 (0.164--4.702)        0.880       0.506 (0.172--1.485)    0.215
  Placenta growth factor (PIGF)                                  0.849 (0.252--2.861)    0.792       4.359 (0.292--65.031)       0.286       0.480 (0.108--2.127)    0.334
  Platelet-derived growth factor subunit B (PDGFsuB)             0.813 (0.577--1.152)    0.246       0.582 (0.275--1.234)        0.158       0.937 (0.635--1.382)    0.742
  Platelet endothelial cell adhesion molecule (PECAM1)           0.600 (0.225--1.602)    0.308       4.398 (0.300--64.463)       0.280       0.393 (0.125--1.238)    0.111
  Prolactin (PRL)                                                1.031 (0.586--1.812)    0.916       1.796 (0.577--5.594)        0.312       0.705 (0.333--1.493)    0.361
  Proteinase-activated receptor 1 (PAR1)                         0.733 (0.243--2.208)    0.580       1.501 (0.152--14.851)       0.729       0.638 (0.179--2.269)    0.487
  Protein S100-A12 (EN-RAGE)                                     1.179 (0.627--2.216)    0.609       1.509 (0.470--4.847)        0.489       1.088 (0.497--2.380)    0.832
  Proto-oncogene tyrosine−protein kinase Src (SRC)               0.705 (0.418--1.186)    0.188       0.962 (0.350--2.641)        0.939       0.650 (0.347--1.218)    0.178
  P-selectin glycoprotein ligand 1 (PSGL-1)                      1.749 (0.222--13.749)   0.595       62.819 (0.284--13874.08)    0.133       0.670 (0.060--7.443)    0.744
  Receptor for advanced glycosylation end products (RAGE)        0696 (0.260--1.863)     0.470       7.234 (0.529--98.950)       0.138       0.306 (0.087--1.082)    0.066
  Renin (REN)                                                    1.438 (0.816--2.533)    0.209       2.332 (0.696--7.819)        0.170       1.073 (0.527--2.181)    0.847
  Resistin (RETN)                                                0.704 (0.335--1.480)    0.354       1.503 (0.231--9.780)        0.670       0.651 (0.276--1.534)    0.326
  SIR2-like protein (SIRT2)                                      0.908 (0.674--1.224)    0.526       0.856 (0.533--1.375)        0.521       0.960 (0.654--1.408)    0.834
  Spondin 1 (SPON1)                                              0.515 (0.154--1.724)    0.282       1.677 (0.050--56.731)       0.773       0.435 (0.114--1.657)    0.222
  ST2 protein (ST2)                                              0.975 (0.473--2.012)    0.946       13.638 (1.211--153.533)     **0.034**   0.604 (0.258--1.411)    0.244
  Stem cell factor (SCF)                                         0.822 (0.272--2.488)    0.729       2.421 (0.182--32.147)       0.503       0.566 (0.158--2.023)    0.381
  T-cell immunoglobulin and mucin domain 1 (TIM)                 1.448 (0.784--2.677)    0.237       1.152 (0.296--4.484)        0.838       1.548 (0.766--3.129)    0.223
  Thrombomodulin (TM)                                            1.361 (0.396--4.684)    0.624       269.71 (3.057--23798.388)   **0.014**   0.497 (0.115--2.149)    0.349
  Tissue factor (TF)                                             1.219 (0.346--4.297)    0.758       6.166 (0.308--123.627)      0.234       0.752 (0.174--3.246)    0.702
  Tissue-type plasminogen activator (tPA)                        0.612 (0.284--1.322)    0.211       0.683 (0.099--4.715)        0.699       0.581 (0.248--1.360)    0.211
  TNF-related activation−induced cytokine (TRANCE)               0.560 (0.262--1.198)    0.135       2.143 (0.324--14.187)       0.429       0.313 (0.123--0.799)    **0.015**
  TNF-related apoptosis-inducing ligand (TRAIL)                  1.554 (0.379--6.375)    0.541       4.111 (0.247--68.385)       0.324       1.120 (0.214--5.866)    0.893
  TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2)     1.185 (0.349--4.021)    0.786       2.140 (0.108--42.467)       0.618       1.128 (0.276--4.611)    0.867
  Tumor necrosis factor receptor superfamily member 6 (FAS)      0.906 (0.297--2.766)    0.862       6.474 (0.575--72.853)       0.130       0.475 (0.120--1.879)    0.289
  Tumor necrosis factor ligand superfamily member 14 (TNFSF14)   2.401 (0.840--6.860)    0.102       3.224 (0.327--31.749)       0.316       2.254 (0.699--7.271)    0.174
  Tumor necrosis factor receptor 1 (TNFR1)                       1.419 (0.407--4.944)    0.582       4.016 (0.304--52.991)       0.291       1.023 (0.226--4.634)    0.977
  Tumor necrosis factor receptor 2 (TNFR2)                       1.401 (0.546--3.592)    0.483       3.164 (0.324--30.891)       0.322       1.209 (0.412--3.545)    0.729
  Urokinase plasminogen activator surface receptor (UPAR)        3.070 (0.879--10.726)   0.079       4.499 (0.267--75.939)       0.297       3.195 (0.699--14.610)   0.134
  Vascular endothelial growth factor A (VEGF-A)                  1.094 (0.309--3.870)    0.889       5.119 (0.293--89.384)       0.263       0.785 (0.182--3.382)    0.745
  Vascular endothelial growth factor D (VEGF-D)                  1.093 (0.478--2.499)    0.833       2.614 (0.364--18.754)       0.339       0.957 (0.451--2.032)    0.909

Significant values are indicated in bold.

![**(A)** Odds ratios and 95% confidence intervals (corrected for age, sex, and presence of AF) for biomarkers with increased or decreased odds for having AVC in the total population, female and male populations. Significant markers are displayed in red. Left panel: Total population, middle panel: female population, right panel: male population. **(B)** Unadjusted boxplots of seven biomarkers found to be significantly different between patients (male/female) with and without AVC. Median and interquartile ranges are shown. GAL, galanin peptides; MCP1, Monocyte chemotactic protein 1; PAPPA, Pappalysin-1; TRANCE, TNF-related activation induced cytokine; FGF23, Fibroblast growth factor 23; ST2, ST2-protein; IL1RA, Interleukin 1 receptor antagonist receptor.](fcell-08-00604-g001){#F1}

The abovementioned differences of IL1RA and PAPPA were driven by the male population \[IL1RA: OR 2.79 (1.16--6.70), *p* = 0.022 and PAPPA: OR 0.30 (0.11--0.84), *p* = 0.021 respectively\]. Furthermore, TRANCE and fibroblast growth factor 23 (FGF23) were lower and monocyte chemotactic protein 1 (MCP1) was higher in males with AVC than without AVC \[TRANCE: OR 0.32 (0.12--0.80), *p* = 0.015; FGF23: OR 0.41 (0.45--2.29), *p* = 0.048 and MCP1: OR 2.64 (1.02--6.81), *p* = 0.045\] ([Figure 1](#F1){ref-type="fig"}).

In the female population, galanin peptides (GAL) and ST2 protein (ST2) odds ratios were higher in females with AVC than in females without AVC \[GAL: OR 12.38 (1.31--116.69), *p* = 0.028; ST2: OR 13.64 (1.21--153.33), *p* = 0.034\] ([Figure 1A](#F1){ref-type="fig"}).

Distributions of biomarkers significantly associated with AVC are shown in [Figure 1B](#F1){ref-type="fig"}.

Discussion and Conclusion {#S4}
=========================

In this study we show differential expression differences in seven circulating biomarkers that might be associated with AVC in early stage aortic valve calcification. These biomarkers are involved in all three processes relevant for aortic valve degeneration, namely inflammation, fibrosis and calcification. Moreover, we report higher expression of fibrosis markers in the early phase of AVC in females, whereas higher expression of calcification and inflammatory markers were found in males.

The progressive character of aortic stenosis and the absence of a medication-based treatment triggered cardiovascular research to identify more precise mechanisms underlying the initiation of AVC and interactions between different pathways ([@B32]; [@B10]; [@B17]; [@B29]; [@B30]). Studies investigating in a follow-up design the potential role of circulating biomarkers in aortic stenosis are scarce and current guidelines only recommend repeated measurements of markedly elevated natriuretic peptides. Whilst these are incorporated in the most recent guidelines, their actual role in clinical management is not clearly defined ([@B5]). Emerging studies investigate the potential utility of other biomarkers, such as troponin-T, troponin-I, ST2, growth differentiation factor-15 (GDF-15) and galectin-3 ([@B33]; [@B8]; [@B22]; [@B23]; [@B3]; [@B18]; [@B35]). A recent study investigating multiple biomarkers of cardiovascular stress revealed that a combination of GDF-15, sST2, and NT-proBNP provided prognostic implications in patients with AS, and with that, a net improvement in risk stratification for mortality after both conventional aortic valve replacement and TAVI ([@B24]). Therefore, multiple biomarkers reflecting various disease mechanisms will be useful in diagnosing aortic valve disease progression.

Recently, it was proposed that in aortic valve disease, sex-specific mechanisms should be investigated in future studies ([@B37]). Women who develop severe aortic valve disease have a lower valvular calcium content when compared to men ([@B1]), suggesting a more dominant role for fibrosis in disease progression in women. The effects of estrogen and testosterone are thought to play a role in determination of the dominance of fibrosis in women vs. the calcification dominance in men ([@B37]). Therefore, we used a multiple biomarker approach to reflect disease mechanisms, and in our study, we confirm a higher expression of ST2 (myocyte stress and fibrosis; [@B34]; [@B24]; [@B7]) and galanin peptides (myocardial remodeling in response to stress; [@B39]) in association with AVC in women. In men, aortic valve disease is considered to be dominated by calcification, and in the current study lower expression levels of TRANCE (or RANKL) were associated with AVC. TRANCE has been shown to promote matrix calcification by inducing expression of osteoblast-associated genes, indicating a transition toward an osteogenic environment ([@B21]). However, in our study we investigate the early stages of AVC, indicated by the low Agatston scores present in our patient population. Also lower expression of pappalysin-1, involved in insulin-like growth factor-1 signaling and osteoblast differentiation of valvular interstitial cells (VICs) ([@B9]), was associated with AVC in men. Additionally, lower expression of FGF23, a phosphatonin regulating phosphate levels involved in metabolic bone disease and vascular calcification, was associated with AVC in men. These data suggest that triggers for VIC phenotype change differ between phases of aortic valve disease progression. Moreover, circulating biomarkers involved in inflammation, oxidative stress and endothelial activation (IL1RA, MCP-1) ([@B15]; [@B19]) showed higher expression which is in line with previous reports that inflammation and oxidative stress relates to increased calcification ([@B2]). Additionally, our data confirm that AVC is actively regulated involving cellular and humoral factors that may offer targets for diagnosis and intervention. The results of the current study show new insights in biomarkers involved in aortic valve disease in a low risk population without significant risk factors for AVC. Therefore, our study adds valuable information to increase knowledge on the mechanisms of aortic valve disease. However, cautious interpretation is warranted. This retrospective, cross-sectional study with an explorative nature has a relatively small sample size, especially when stratified by sex. Furthermore, the size of this study does not allow for multiple corrections (for instance for aspirin, which possibly is associated with fibrosis). Therefore, the biomarker panel results need to be confirmed in larger studies.

Genesis and progression of aortic valve disease is a complex process. We found a number of biomarkers involved in several processes associated with aortic valve disease. Single biomarkers clearly lack sensitivity to form the base for analyzing all processes involved at different stages (including the initiation phase) of the disease, given that these biomarkers might be derived from different sources within the body. Investigating panels of biomarkers in future studies can overcome this problem in addition to further development of imaging technologies to visualize the disease in its earliest/premature phases. Moreover, integration of (a combination of) specific biomarkers and imaging could more successfully assess the risk of rapid progression, which would facilitate patient counseling and help personalize follow up of patients. Ultimately, gaining knowledge in the processes involved in the genesis and the progression phases of aortic valve disease will provide us with opportunities to investigate potential therapeutic targets to slow/reduce/regress AVC and disease progression. With that, the opportunity to delay surgical interventions in patients with aortic valve disease might be imminent.
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